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1. Introduction
There is considerable body of evidence to suggest that the effect of obesity as a major risk factor
of chronic diseases differ due to variation in genetic predisposition and ethnic differences. This
is due probably to the difference in body habitus and the distribution of adipose tissue. It is
shown that Asians have a higher proportion of abdominal obesity compared to other ethnic
groups and carry greater risk for diabetes, hypertension and coronary vascular diseases at a
lower level of body mass index(BMI) compared to other populations. [1-3]. Japanese are
reported to carry twice the risk of developing diabetes at all levels of BMI compared to
Caucasians [4]. Therefore with a wide variety of studies reporting the importance of ethnicity
playing an important role in the distribution of total body fat has created a need to identify a
biomarker(s) or risk marker for ethnic heterogeneity in the development of chronic diseases.
In this regard adipocytokines adiponectin, leptin and resistin are considered as potential
candidates to delineate the mechanisms involved in such ethnic differences related to chronic
diseases. Adiponectin and leptin are reported to show reciprocal relationship with increasing
adiposity. It is demonstrated that adiponectin levels reflect visceral adiposity and leptin the
subcutaneous one. It is also reported that serum adiponectin levels are lower in Chinese,
Malay, Japanese, Koreans, south Asians compared to Caucasians. [5]There is another adipo‐
cytokine which is related to adiposity. This adipocytokine was reported to resist the action of
insulin and so it is named as Resistin. It is shown that Resistin is present more in visceral
adipose tissue compared to other fat depots and a diet rich in fat induces greater secretion of
resistin.[6] The adiponectin, leptin and resistin trio could be the biomarkers of ethnic hetero‐
geneity.
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Obesity is a major public health concern of Libya with higher prevalence of obesity related
diseases hypertension, type 2 diabetes (T2DM) and coronary vascular disease.[7] Therefore,
the present preliminary study was undertaken in Libyan subjects with their unique ethnicity,
life style and cultural habits to demonstrate whether such differences occur in serum adipo‐
nectin, leptin and resistin levels in relation to adiposity particularly visceral adiposity. It was
shown that BMI and Waist circumference could be taken as markers of subcutaneous obesity
and abdominal obesity respectively. Along with these anthropometric measurements glycemic
status, lipid profile were studied and correlated with adiponectin, leptin and resistin levels in
obese and type 2 diabetes (T2DM) subjects.
2. Subjects taken for the study
The subjects included in the study were local Libyan subjects, Benghazi. Informed consent was
taken from each participant and approval for the study taken from Institute Ethics Review
Board(Faculty of Medicine, Benghazi University, Benghazi).
3. Anthropometric measurements
Height, weight, waist circumference, were measured. Their age, duration of diabetes and
medicine usage as well as personal and family history were noted.The measurements and
examinations were carried out by the same physician.
BMI was calculated by the formula: Weight (kg)/Height2 (m2). Normal BMI was taken as 18-25
kg/m2. Patients with BMI values of 25-30 kg/m2 were classified as overweight; and those with
BMI ≥30 kg/m2 were considered obese.
Waist circumference (cm) was measured parallel to the midpoint between the lower limit of
the 12th costa and the ischial spine. The limits were accepted as >102 cm in men, and >88 cm in
women (ATP: adult treatment panel III criteria).
4. Sample collection
Among the 1500 patients visiting the Department of Medicine, Faculty of Medicine, Benghazi
University hospital for medical check up, 650 subjects were taken for the study. 200 subjects
taken as controls(100 –males; 100-females) and 250 (100-males; 150-females) subjects formed
the obese group and 200 formed the diabetes group(100 males and 100 females).Fasting blood
samples were collected in vacutainer tubes with a gel separator and in heparinized tubes for
HbA1C measurements and were centrifugated at 2000 rpm for 15 min at 4°C after an incubation
period of 30 min. All biochemical variables were measured on the same day of the blood
collection. Remaining serum specimens were stored at −20°C until analysis of adiponectin,
leptin and resistin levels.
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5. Biochemical methods
Serum glucose, total cholesterol (TC), HDL-cholesterol (HDL-C), triglyceride (TG) were
measured by an enzymatic colorimetric method.Serum adiponectin levels were measured by
enzyme linked immunosorbent assay (ELISA) with a sensitivity of 3 ng/ml. Serum leptin levels
were measured by an active human leptin ELISA (DSL, Diagnostic System Laboratories, USA)
with a sensitivity of 0.05 ng/ml. Serum resistin levels were measured by ELISA (Linco Research,
USA) with a sensitivity of 0.16 ng/ml.
6. Calculations
Low-density lipoprotein-cholesterol (LDL-C) was calculated using the Friedewald formula.
Standing height and body weight were measured with the subjects dressed in light indoor
clothing without shoes. Body mass index (BMI) was calculated as weight divided by the square
of the height (kg/m2).
7. Statistical analyses
Statistical analysis was performed using SPSS for Windows (Statistical Package for the Social
Sciences, version 20.0; SSPS Inc. Chicago, IL, USA). The normal distribution of the variables
was evaluated using the Shapiro-Wilk test. The Mann-Whitney U test was used for the
comparison of variables which were not normally distributed, and the independent Student’s
t-test for the comparison of variables which were normally distributed. The Pearson and
Spearman tests were used for the evaluation of correlations among the variables according to
the distribution of variables. P<0.05 was accepted as indicative of statistical significance. The
results of variables with a normal distribution were expressed as mean ± SD and those with a
non-Gaussian distribution were expressed as median (25th–75th percentile).
8. Ethical considerations
The study was carried out in accordance with the Declaration of Helsinki. Informed consent
was obtained from all the patients for the initial study. The protocol was approved by the
Medical Ethics Committee of the Faculty of Medicine, Benghazi University, Benghazi,Libya.
Additional informed consent was obtained for the present study.
Results: Table.1. shows the differences in waist circumferences reported for various ethnic
groups
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Source *Adapted from Zimmet and Alberti [2006] [8]; ** present study
Table 1. Ethnic differences in Waist circumferences
Indicator Cut off Points Risk of Metabolic complications
Waist circumference >94cm(M), >80cm(W) Increased
Waist circumference >102cm(M), >88cm(W) Substantially increased
W/H ratio >0.90(M), >0.85(w) Substantially increased
M: men; W: women
Table 2. World Health Organization (WHO) cut off points and risk of Metabolic complications[9]
The mean BMI in Libyan adults is reported to be 27.7 kg/m2 (26.4 kg/m2 in men and 29 kg/m2
in women), and the mean waist circumference is 93.3 cm. [10] In the present study compared
to other ethnic groups Libyan Men and women have higher BMI and Waist circumference
carrying higher risk for metabolic complications as well as for chronic diseases. (BMI 25-30;
(29.5) and 30 to 35 (34.5)respectively in normal as well as obese controls). Waist circumference
104cm; 114 cm for normal and obese subjects respectively; Waist circumference to Hip
circumference; 0.97 for both men and women subjects.(W/H ratio). The normal control group
had higher BMI as well as higher waist circumference indicating both subcutaneous fat and
visceral fat are increased in the subjects studied.
*Chinese *Malay *Asian Indian *Libyan P Anova
Males-Total Adiponectin(µg/ml) 3.10±1.79 2.97±1.80 2.97±1.75 1.97±1.05 0.01
Females(Total Adiponectin(µg/ml) 4.60±2.50 4.28±2.52 3.83±1.95 2.45±1.10 0.001
*Adapted from Chin Meng Khoo et al.[11] ** present study
*P value for comparison between the ethnic groups in men; †P value for comparison between the ethnic groups in
women. The values for adiponectin for both Libyan men and women were comparatively lower than the values report‐
ed for other ethnic groups like Chinese, Malay, Asian Indian groups.
Table 3. Ethnic variation in Serum Adiponectin levels
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Control-normal Obese controls Diabetes P-value Adjusted P-value
Leptin, ng/mL 13.90 ± 3.16 *28.10 ± 5.00 **32.25±6.50 *0.000**0.000 P<0.001
Adiponectin, µg/mL 2.01± 1.05 1.90± 0.75 *5.45±1.05 **0.009 P<0.01
Resistin, ng/mL 6.80 ± 3.70 *18.46 ± 8.80 **24.45±9.50 *0.0039**0.000
P<0.01
P<0.001
Table 4. Serum Adiponectin, Leptin and Resistin levels in normal, obese and Diabetic Libyan patients
The serum levels of adiponectin did not show significant difference in their values between
controls and obese subjects.The adiponectin level in diabetic subjects is significantly higher
than the control subjects. The serum levels of leptin and resistin were significantly higher for
obese and T2DM compared to normal controls.
Control Obese Diabetes p.value







Waist circumference(cm) 104 * 112 **120 *<0.001**<0.001
FastingBlood glucose(mg/dL) 89.50±15.50 105.50±20.50 *155.50±24.50 *<0.001
Glycated hemoglobin(%) 5.50±1.05 6.45±1.25 *8.90±1.50 *<0.001
Total Cholesterol (mg/dL) 128.45±18.40 148.20±24.50 *175.50±25.50 *<0.001
HDL-cholesterol(mg/dL 37.45±4.50 35.50±5.50 *32.50±6.50 <0.05
LDL cholesterol (mg/dL) 95.45±12.50 105.5±14.00 *125.00±7.50 *<0.05
Non-HDL cholesterol(mg/dL) 91.00±7.50 *112.70±8.00 *143.00±12.50 <0.05
Triglycerides(mg/dL) 99.50±10.50 105.50±12.00 *145.00±25.50 <0.01
Table 5. Serum glucose, glycated hemoglobin (HbA1c) and Lipid Profile in the Libyan Subjects
There was no marked differences between the control group and obese group with respect to
the serum levels of glucose, HbA1c, total cholesterol, HDL-cholesterol, LDL-cholesterol and
triglycerides. There were marked increases in total cholesterol, LDL cholesterol, triglycerides
with a marked fall in HDL cholesterol in diabetec subjects (dyslipidemia)
A marked increase was observed in non-HDL cholesterol in obese and diabetics compared to
the control group.
The levels of serum total cholesterol and HDL cholesterol are comparatively lower for local
Libyan subjects when compared to South Asians and Non South Asians.




Of the anthropometric measures Body mass index (BMI), waist circumference and waist-hip
ratio, waist circumference were reported to be more closely related to abdominal obesity and
T2DM. Majority of the studies supported the view that there is no optimal cut-off point that
can be universally applied. It was suggested that country or region-specific cut off points may
be used. [13-14]
Data available in the literature suggest that lower waist circumference and waist-hip ratio cut
off point for Asians-85cm and 80 cm, W/H ratio 0.9 and 0.8 for men and women, respectively.
[15-17] A study from Tunisia provided a cut‐off point for waist circumference (for obesity,
diabetes,and CVD) of 85 cm for both men and women, based on sensitivity being equal to
specificity.[18]. The values for BMI and WC for Arab Nations are reported to be similar to
European population.[19]
Obesity is a major public health concern for Libya. It is reported that about 30% of Libyan
adults are obese. About 64% of Libyan adults are either overweight or obese. In the present
study BMI values for control subjects were 29.5, 34.5 for obese subjects and 36.50 for T2DM
subjects. WC values for control was 104cm,114 cm for obese subjects and 120 for T2DM subjects.
These values clearly indicate that majority of the population are either over-weight or obese.
This is supported by data that obesity related diseases like type 2 diabetes (T2DM), hyperten‐
sion, poly cystic ovarian disease (PCOD) are on the rise in Libya. [7, 20-22]. There is a dire need
for finding risk markers for obesity and obesity related disorders.
There is a shift in focus to find out whether ethnic diversity could be a factor in the distribution
pattern of adiposity variation in different populations. Few studies have stated that adipocy‐
tokines particularly adiponectin values differ for different population indicating that adipo‐
nectin could be taken as a biomarker of ethnic heterogeneity. When compared to other
population serum adiponectin values were comparatively lower for Libyan subjects. Serum
leptin and resistin levels were higher for obese and T2DM subjects compared to control
ones.Paradoxically the serum levels of adiponectin were higher for T2DM subjects contrary to
reports that there is hypoadiponectinemia in T2DM. Hyperadiponectinemia reported quite
*Non-south Asians *South Asians **Libyan P value
Total cholesterol




(mg/dL) 47.55±6.50 41.45±8.50 *37.5.±5.50
0.033
<0.05
Triglcyerides(mg/dL) 145.12±24.50 140.6±25.50 145.5±12.20 0.45
*France et al [12] ** present study
Table 6. Serum lipid profile in different ethnic groups
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contrary to the earlier observations is suggested to be due to the presence of severe insulin
resistance possibly to genetically defective insulin receptors. [23]
This finding emphasizes that insulin receptor has a critical role regulating adiponectin
synthesis as well as clearance. Patients who have anti-insulin receptor antibodies may be
responsible for severe insulin resistance (Type B IR) who show a significant increase in serum
adiponectin levels. Such a finding brings out considerable focus on the adiponectin –insulin
sensitivity concept. Rather it opens up for more avenues of research to exactly elicit the
adiponectin’s role in insulin sensitivity and suggests that insulin effect on adiponectin
metabolism is undermined.[23]
In the present study T2DM Libyan patients showed marked increase in serum adiponectin
levels compared to the control subjects. These subjects had higher insulin levels and insulin
resistance shown by HOMA index. The duration of diabetes in these patients is 10 years or
more.The results are not shown here.
This finding appears unique to Libyan diabetic subjects. It is reported earlier that adiponectin
levels in Libyan subjects are comparatively lower when compared to European or western
population in general. Therefore serum adiponectin levels seem to be determined by ethnic
heterogeneity reflected by the distribution of adipose tissue and its genetic regulation of
adiponectin’s synthesis, secretion and degradation. Possibly the reportedly higher BMI in the
population with a higher basal insulin levels (accompanied by insulin resistance) might have
an suppressive effect on adiponectin formation or clearance.
Insulin resistance(IR) is now generally accepted to be the primary metabolic defect of T2DM
[24]. IR is defined as a state that requires more insulin to obtain the biological effects achieved
by a lower amount of insulin in the normal state [25].
In contrast to other adipokines, circulating levels of adiponectin correlate inversely with body
fat and IR in humans [26] and rodent models [25].). It circulates at high levels in human plasma
accounting for approximately 0.01% (0.5-30 µg/mL) of all plasma protein in normal individuals
[27], 1000-fold higher than other hormones such as leptin and insulin. Gender has an effect on
concentrations of adiponectin, with females having higher levels than males [28]. It is also well
known that adiponectin levels increase with age, however the cause for this increase is still
unknown [29]
The molecule adiponectin is a 244-amino-acid long adipokine secreted from adipocytes. The
gene product is a 30kD protein [30], however this is not found in circulation. Adiponectin
automatically self-binds to form larger structures and there are different multimeric forms
including low molecular weight (LMW) trimers, middle molecular weight (MMW) hexamers,
high molecular weight (HMW) oligomeric structures and finally globular adiponectin (gC1q
domain)[27]. It has been proposed that this globular fragment is generated by proteolytic
cleavage of adiponectin multimers by leukocyte elastase secreted from activated monocytes
and/or neutrophils [24]; however the pathophysiological importance of this cleavage remains
to be determined. Structurally, the globular form of adiponectin lacks the collagenous domain
necessary for multimerization. Adipocytes secrete both the low-molecular weight and high-
molecular weight forms of adiponectin in vivo and in vitro. Thus, the low-molecular weight
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and high-molecular weight forms of adiponectin are the predominant forms in serum whilst
smaller complexes such as the trimer are virtually undetectable. [31].
10. Monomeric structure
There are four distinct regions of adiponectin. The protein starts with a short signal sequence
which acts to target the hormone for secretion outside the cell, then it leads into a short region
that is variable between species, followed by an amino-acid region that shows similarity with
collagenous protein, and finally ending with a globular domain. The three dimensional
structure of its C-terminal globular domain is similar to that of tumor necrosis factor–alpha
(TNF-α), even though there is no sequence homology at the primary structure level. [32].
11. Higher order structures
Initially, three adiponectin molecules associate through disulphide bonds within the collage‐
nous domains of each monomer to form bouquet-like higher order structure, a homotrimer.
The trimers continue to self-associate and form hexamers [33].
The levels of the higher order structures are sexually dimorphic [34], where females have
increased proportions of the high-molecular weight forms. The varying forms have altered
biological activity and therefore may also have separate functions. The gC1q domain and the
trimeric forms of adiponectin activate AMP Kinase in skeletal muscle and lead to increased
fatty acid oxidation and reduction in glucose concentrations, whereas the hexameric and full
length HMW forms are thought to activate nuclear factor kappa B (NF-κB) pathways [35]. The
proportion of HMW adiponectin within adipose tissue is higher than in blood plasma,
suggesting regulation at the level of secretion and is a mechanism of adiponectin complex
distribution. All isoforms of the molecule are stable in circulation having a relatively longer
half life (half-life of ~15hrs) [24].
12. Receptors and signaling
Two receptors have been identified that bind adiponectin: Adipo R1 and Adipo R2. AdipoR1
was first identified when encoding cDNA was isolated from human skeletal cDNA library by
screening for adiponectin binding [36]. The AdipoR2 was identified later due to its striking
homology to AdipoR1. Both are surface membrane proteins [36] and have homology to G
protein-coupled receptors.. These receptors contain seven transmembrane domains, but are
structurally and functionally distinct from other known GPCRs (G-protein-coupled recep‐
tors[37]. The receptors have different affinities to the various molecular forms of adiponectin.
AdipoR1 and AdipoR2 are found in liver, muscle and adipose tissue in humans; however
AdipoR1 is predominantly expressed in skeletal muscle whereas AdipoR2 is more predomi‐
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nant in the liver [36]. AdipoR1 is a high-affinity receptor for globular adiponectin as well as
having a lower affinity for full length adiponectin. In contrast the AdipoR2 receptor has an
equal intermediate affinity for globular and full length HMW adiponectin [36]. The receptors
affect a very important cellular metabolic rate control point, by targeting AMP-activated
protein Kinase (AMPK), downstream. AMPK is a stress induced kinase that is activated in
response to depleting Adenosine triphosphate (ATP) or increasing Adenosine monophosphate
(AMP) levels. AMPK activates ATP and generates catabolic processes such as fatty acid
breakdown and glycolysis and shuts down ATP-consuming processes such as lipogenesis [37].
Expression of these receptors is correlated with insulin levels [24]. A review of studies
involving the adiponectin receptors suggests that they may have an important role in adipo‐
nectin physiology. Key findings suggest that changes in expression of AdipoR isoforms in
skeletal muscle (rather than total circulating adiponectin concentrations) may be of physio‐
logical importance [38]. More recently, by means of expression cloning, T-cadherin has been
recognized as an adiponectin receptor on vascular endothelial cells and smooth muscle [36].
The expression of this cadherin molecule is known to be correlated with atherosclerosis [33].By
genomic sequence analysis, Saito et al. determined that the ADIPOQ gene spans 16 kb,contains
3 exons and 2 introns and the promoter lacks a TATA box(a sequence involved in the process
of transcription). The exon-intron organization of this gene was very similar to that of obese
gene,encoding leptin. Saito et al. reported that the ADIPOQ gene was located on human
chromosome band 3q27using chromosome mapping of this gene by fluorescence in situ
hybridization (FISH) taking genomic DNA fragment as a probe [39]. It is reported that a
mutation in this gene is associated with low serum adiponectin levels and T2DM[41].
It has been reported that blood concentrations of adiponectin fall from 20-50% in humans and
mice respectively with the administration of insulin, thus implying that the effect of insulin to
lower adiponectin levels may involve inhibition of adipocyte secretion. Plasma adiponectin
levels have also been shown to be decreased in an obese rhesus monkey model that frequently
develops Type 2 Diabetes [42] Many prospective studies [43-45] have shown that lower
adiponectin levels are associated with a higher incidence of diabetes in humans and more
importantly the decrease in plasma adiponectin levels was in parallel with the decrease in
insulin sensitivity [25]. This finding is further supported by a recent analysis of 13 prospective
studies, which found that higher adiponectin levels were associated with a lower risk of Type
2 Diabetes across diverse populations [45-46].
The levels of serum total cholesterol and triglycerides are comparatively lower for local Libyan
subjects when compared to South Asians and Non South Asians.[47] The serum level of total
HDL cholesterol is also low in Libyan subjects probably due to the lowered levels of total
cholesterol and triglycerides.[47].
A marked increase was observed in non-HDL cholesterol in obese individuals compared to
the control group.[48] and there was a marked fall in HDL cholesterol indicating that dyslipi‐
demia is prevalent in local Libyan subjects
This preliminary study indicates that the distribution of fat in Libyan population varies from
other populations. There is a marked increase in total as well as abdominal adiposity indicated
by anthropometric measurements. The serum level of adiponectin is low in this population
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along with comparatively HDL cholesterol with a marked increase in non-HDL cholesterol.
Therefore further studies are being carried out to bring out the nature unique ethnic diversity
in the population as well as to recommend that an overall reduction of body weight in the
population need to be considered to lower risk of metabolic disorders.
Apart from these observations the serum levels of adiponectin were found to be lower for the
Libyan subjects and its level was increased in T2DM subjects.
This observation seems to suggest whether serum adiponectin level in Libyan subjects can be
taken as a biomarker of ethinic heterogeneity.
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